Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the ...

Shares of Novo Nordisk climbed nearly 7% on Wednesday after the company said sales of its obesity drug Wegovy are expected to ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Pharmaceutical company Charles River Laboratories has reached a settlement with activist investor Elliott Investment Management to add four new directors to its board and launch a strategic review of ...

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...